Perioperative ctDNA-Based Molecular Residual Disease Detection for Non–Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1) https://t.co/6EQRXZ5wxl
RT @PazAresLab: The analysis of perioperative ctDNA is effective in early detection of molecular residual disease and prediction of postope…
The analysis of perioperative ctDNA is effective in early detection of molecular residual disease and prediction of postoperative relapse in NSCLS according to Xia et al https://t.co/XBTO7nkAna
RT @DrBivas: Ongoing MERMAID studies will probably answer to the question.
RT @StephenVLiu: MRD in NSCLC? Report @CCR_AACR looks at perioperative ctDNA after surgery for NSCLC. Using a 769-gene panel, detectable ct…
RT @StephenVLiu: MRD in NSCLC? Report @CCR_AACR looks at perioperative ctDNA after surgery for NSCLC. Using a 769-gene panel, detectable ct…
Our #DetermaRX testing is the first & only molecular test for NSCLC. The assay gives thoracic surgeons the confidence to understand a patients recurrence risk and medical oncologist an extra layer of information for treatment selection @OncocyteCorp #t
RT @DrJNaidoo: 'Molecular Residual Disease' in early stage NSCLC, in 330 pts with tumor+plasma analyzed by 769 gene panel: - MRD: ctDNA+ po…
RT @DrJNaidoo: 'Molecular Residual Disease' in early stage NSCLC, in 330 pts with tumor+plasma analyzed by 769 gene panel: - MRD: ctDNA+ po…
RT @DrJNaidoo: 'Molecular Residual Disease' in early stage NSCLC, in 330 pts with tumor+plasma analyzed by 769 gene panel: - MRD: ctDNA+ po…
RT @DrJNaidoo: 'Molecular Residual Disease' in early stage NSCLC, in 330 pts with tumor+plasma analyzed by 769 gene panel: - MRD: ctDNA+ po…
RT @DrJNaidoo: 'Molecular Residual Disease' in early stage NSCLC, in 330 pts with tumor+plasma analyzed by 769 gene panel: - MRD: ctDNA+ po…
RT @DrJNaidoo: 'Molecular Residual Disease' in early stage NSCLC, in 330 pts with tumor+plasma analyzed by 769 gene panel: - MRD: ctDNA+ po…
RT @DrJNaidoo: 'Molecular Residual Disease' in early stage NSCLC, in 330 pts with tumor+plasma analyzed by 769 gene panel: - MRD: ctDNA+ po…
RT @DrJNaidoo: 'Molecular Residual Disease' in early stage NSCLC, in 330 pts with tumor+plasma analyzed by 769 gene panel: - MRD: ctDNA+ po…
RT @DrJNaidoo: 'Molecular Residual Disease' in early stage NSCLC, in 330 pts with tumor+plasma analyzed by 769 gene panel: - MRD: ctDNA+ po…
RT @DrJNaidoo: 'Molecular Residual Disease' in early stage NSCLC, in 330 pts with tumor+plasma analyzed by 769 gene panel: - MRD: ctDNA+ po…
RT @DrJNaidoo: 'Molecular Residual Disease' in early stage NSCLC, in 330 pts with tumor+plasma analyzed by 769 gene panel: - MRD: ctDNA+ po…
RT @DrJNaidoo: 'Molecular Residual Disease' in early stage NSCLC, in 330 pts with tumor+plasma analyzed by 769 gene panel: - MRD: ctDNA+ po…
RT @DrJNaidoo: 'Molecular Residual Disease' in early stage NSCLC, in 330 pts with tumor+plasma analyzed by 769 gene panel: - MRD: ctDNA+ po…
RT @DrJNaidoo: 'Molecular Residual Disease' in early stage NSCLC, in 330 pts with tumor+plasma analyzed by 769 gene panel: - MRD: ctDNA+ po…
RT @DrJNaidoo: 'Molecular Residual Disease' in early stage NSCLC, in 330 pts with tumor+plasma analyzed by 769 gene panel: - MRD: ctDNA+ po…
RT @DrJNaidoo: 'Molecular Residual Disease' in early stage NSCLC, in 330 pts with tumor+plasma analyzed by 769 gene panel: - MRD: ctDNA+ po…
RT @DrJNaidoo: 'Molecular Residual Disease' in early stage NSCLC, in 330 pts with tumor+plasma analyzed by 769 gene panel: - MRD: ctDNA+ po…
RT @DrJNaidoo: 'Molecular Residual Disease' in early stage NSCLC, in 330 pts with tumor+plasma analyzed by 769 gene panel: - MRD: ctDNA+ po…
RT @DrJNaidoo: 'Molecular Residual Disease' in early stage NSCLC, in 330 pts with tumor+plasma analyzed by 769 gene panel: - MRD: ctDNA+ po…
'Molecular Residual Disease' in early stage NSCLC, in 330 pts with tumor+plasma analyzed by 769 gene panel: - MRD: ctDNA+ postop d3 +/or 1-mnth - MRD+ assoc with relapse (HR=11.1 p<0.001) - Improved RFS with adjuv thx vs. none in MRD+ pts (HR=0.3; p=0.0
RT @StephenVLiu: MRD in NSCLC? Report @CCR_AACR looks at perioperative ctDNA after surgery for NSCLC. Using a 769-gene panel, detectable ct…
Interesting data!
RT @StephenVLiu: MRD in NSCLC? Report @CCR_AACR looks at perioperative ctDNA after surgery for NSCLC. Using a 769-gene panel, detectable ct…
RT @PTarantinoMD: Striking RFS curves depending on MRD - curves that we’re starting to see in many different cancer types This is the deca…
RT @StephenVLiu: MRD in NSCLC? Report @CCR_AACR looks at perioperative ctDNA after surgery for NSCLC. Using a 769-gene panel, detectable ct…
RT @DoctorJSpicer: Molecular staging > TNM staging #LCSM https://t.co/wxr8ElyZl8
RT @DoctorJSpicer: Molecular staging > TNM staging #LCSM https://t.co/wxr8ElyZl8
Ongoing MERMAID studies will probably answer to the question.
RT @StephenVLiu: MRD in NSCLC? Report @CCR_AACR looks at perioperative ctDNA after surgery for NSCLC. Using a 769-gene panel, detectable ct…
RT @PTarantinoMD: Striking RFS curves depending on MRD - curves that we’re starting to see in many different cancer types This is the deca…
NSCLCで術後の微小残存病変(MRD)をctDNAで評価した研究が発表されました。術後のctDNA陰性群は術後補助療法が入った方が予後不良です。 膀胱がんでは術後にMRDを評価したうえで陽性のみに薬物療法を行う臨床試験が進んでいますが、NSCLCでも進むんでしょうか。
RT @StephenVLiu: MRD in NSCLC? Report @CCR_AACR looks at perioperative ctDNA after surgery for NSCLC. Using a 769-gene panel, detectable ct…
RT @DoctorJSpicer: Molecular staging > TNM staging #LCSM https://t.co/wxr8ElyZl8
The presence of ctDNA positivity at postop day 3 and/or 1-month after surgery was a strong predictor for NSCLC relapse (HR=11.1; P<0.001). ctDNA-positivity had a higher relative contribution to RFS prediction than TNM stage. https://t.co/auEuUn4mBQ
RT @DoctorJSpicer: Molecular staging > TNM staging #LCSM https://t.co/wxr8ElyZl8
RT @StephenVLiu: MRD in NSCLC? Report @CCR_AACR looks at perioperative ctDNA after surgery for NSCLC. Using a 769-gene panel, detectable ct…
RT @PTarantinoMD: Striking RFS curves depending on MRD - curves that we’re starting to see in many different cancer types This is the deca…
RT @PTarantinoMD: Striking RFS curves depending on MRD - curves that we’re starting to see in many different cancer types This is the deca…
RT @StephenVLiu: MRD in NSCLC? Report @CCR_AACR looks at perioperative ctDNA after surgery for NSCLC. Using a 769-gene panel, detectable ct…
RT @StephenVLiu: MRD in NSCLC? Report @CCR_AACR looks at perioperative ctDNA after surgery for NSCLC. Using a 769-gene panel, detectable ct…
RT @StephenVLiu: MRD in NSCLC? Report @CCR_AACR looks at perioperative ctDNA after surgery for NSCLC. Using a 769-gene panel, detectable ct…
RT @StephenVLiu: MRD in NSCLC? Report @CCR_AACR looks at perioperative ctDNA after surgery for NSCLC. Using a 769-gene panel, detectable ct…
RT @StephenVLiu: MRD in NSCLC? Report @CCR_AACR looks at perioperative ctDNA after surgery for NSCLC. Using a 769-gene panel, detectable ct…
RT @StephenVLiu: MRD in NSCLC? Report @CCR_AACR looks at perioperative ctDNA after surgery for NSCLC. Using a 769-gene panel, detectable ct…
RT @StephenVLiu: MRD in NSCLC? Report @CCR_AACR looks at perioperative ctDNA after surgery for NSCLC. Using a 769-gene panel, detectable ct…
RT @PTarantinoMD: Striking RFS curves depending on MRD - curves that we’re starting to see in many different cancer types This is the deca…
Those are truly remarkable results. However, it would be interesting to know what the best number of genes without loosing performance would be. Smaller gene panels might be more cost effective and promote implementation. @isliquidbiopsy
RT @StephenVLiu: MRD in NSCLC? Report @CCR_AACR looks at perioperative ctDNA after surgery for NSCLC. Using a 769-gene panel, detectable ct…
RT @StephenVLiu: MRD in NSCLC? Report @CCR_AACR looks at perioperative ctDNA after surgery for NSCLC. Using a 769-gene panel, detectable ct…
RT @StephenVLiu: MRD in NSCLC? Report @CCR_AACR looks at perioperative ctDNA after surgery for NSCLC. Using a 769-gene panel, detectable ct…
RT @StephenVLiu: MRD in NSCLC? Report @CCR_AACR looks at perioperative ctDNA after surgery for NSCLC. Using a 769-gene panel, detectable ct…
RT @StephenVLiu: MRD in NSCLC? Report @CCR_AACR looks at perioperative ctDNA after surgery for NSCLC. Using a 769-gene panel, detectable ct…
RT @StephenVLiu: MRD in NSCLC? Report @CCR_AACR looks at perioperative ctDNA after surgery for NSCLC. Using a 769-gene panel, detectable ct…
RT @StephenVLiu: MRD in NSCLC? Report @CCR_AACR looks at perioperative ctDNA after surgery for NSCLC. Using a 769-gene panel, detectable ct…
RT @StephenVLiu: MRD in NSCLC? Report @CCR_AACR looks at perioperative ctDNA after surgery for NSCLC. Using a 769-gene panel, detectable ct…
Striking RFS curves depending on MRD - curves that we’re starting to see in many different cancer types This is the decade to learn how to best adapt our adjuvant cancer treatments based on MRD https://t.co/kSJ3PLSc7j
RT @StephenVLiu: MRD in NSCLC? Report @CCR_AACR looks at perioperative ctDNA after surgery for NSCLC. Using a 769-gene panel, detectable ct…
RT @ChristianRolfo: @isliquidbiopsy
RT @StephenVLiu: MRD in NSCLC? Report @CCR_AACR looks at perioperative ctDNA after surgery for NSCLC. Using a 769-gene panel, detectable ct…
RT @aadel_chaudhuri: Nice data showing #liquidbiopsy #ctDNA #MRD detection is predictive (not merely prognostic) in lung cancer. Similar to…
Nice data showing #liquidbiopsy #ctDNA #MRD detection is predictive (not merely prognostic) in lung cancer. Similar to IMvigor011 for bladder cancer. In future: ctDNA MRD status could be used to personalize the use of adjuvant therapy for stage I-III lung
RT @StephenVLiu: MRD in NSCLC? Report @CCR_AACR looks at perioperative ctDNA after surgery for NSCLC. Using a 769-gene panel, detectable ct…
RT @StephenVLiu: MRD in NSCLC? Report @CCR_AACR looks at perioperative ctDNA after surgery for NSCLC. Using a 769-gene panel, detectable ct…
👇🏾Very intriguing. 🆒🆕@CCR_AACR @AACR Benefit of adjuvant therapy in #NSCLC #LCSM in #ctDNA➕🆚➖ HR 0.1-0.3 in➕🆚 not significant in➖ They got 3️⃣🩸🧪 ✔️Pre-operative ✔️3-day (2-14 days) ✔️1 month (4-6 weeks) 📖 “shedding hypothesis” @OncoAlert https://t.co
@isliquidbiopsy
RT @StephenVLiu: MRD in NSCLC? Report @CCR_AACR looks at perioperative ctDNA after surgery for NSCLC. Using a 769-gene panel, detectable ct…
RT @DoctorJSpicer: Molecular staging > TNM staging #LCSM https://t.co/wxr8ElyZl8
RT @DoctorJSpicer: Molecular staging > TNM staging #LCSM https://t.co/wxr8ElyZl8
RT @DoctorJSpicer: Molecular staging > TNM staging #LCSM https://t.co/wxr8ElyZl8
RT @StephenVLiu: MRD in NSCLC? Report @CCR_AACR looks at perioperative ctDNA after surgery for NSCLC. Using a 769-gene panel, detectable ct…
RT @DoctorJSpicer: Molecular staging > TNM staging #LCSM https://t.co/wxr8ElyZl8
RT @StephenVLiu: MRD in NSCLC? Report @CCR_AACR looks at perioperative ctDNA after surgery for NSCLC. Using a 769-gene panel, detectable ct…
Molecular staging > TNM staging #LCSM https://t.co/wxr8ElyZl8
In the prospective LUNGCA-1 study in pts with stage I-III NSCLC, ctDNA-defined MRD+ pts who received adjuvant therapies had improved RFS over those not receiving adjuvant therapy, whereas adjuvant therapy was associated with lower RFS in MRD- pts: https://
Perioperative ctDNA-based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multic… https://t.co/t0EH4Cuvvj https://t.co/z74Xq3sbzK
PubMed_ Perioperative ctDNA-based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1) https://t.co/Pm27h5TYy4